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ABSTRACT
Objective: Estimate the prevalence of benzodiazepine use by adult women at a Family 
Health Unit and identify the risk factors associated with this usage. Method: Quantitative 
cross-sectional study that employed secondary data developed at a Family Health Unit in 
the state of São Paulo, Brazil. We collected the data from the following sources: medical 
charts, registration forms, and the archive of prescriptions from the pharmacy at the 
referred health unit. We employed the chi-squared, Student’s t, and Mann-Whitney tests, 
as well as logistic regression analysis. Results: We identified 81 benzodiazepine users 
amongst 1,094 adult women (7.4%). Regarding the risk factors, the comparison between 
the groups of benzodiazepine users (n = 64) and non-users (n = 70) showed that having a 
chronic disease and using other psychotropic drugs were significantly associated with the 
use of benzodiazepines. Conclusion: The prevalence found was lower than the described 
in previous studies performed in Primary Health Units. The group that must receive 
greater attention regarding the consumption of benzodiazepines is that of middle-aged 
women or older, with low education levels, and chronic illnesses.
DESCRIPTORS
Psychotropic, Drug; Women; Prevalence; Risk Factors; Chronic Disease; Family Health 
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INTRODUCTION
Brazil has been pointed out as one of the leading world 
consumers of benzodiazepines (BZD), and the indiscrimi-
nate use of such drugs constitutes a significant public health 
problem, primarily due to their side effects and the poten-
tial to induce tolerance and long-term psychological and/
or physiological dependency(1-4). 
Women are more susceptible to receiving BZD pre-
scriptions, and the refilling of the prescription is not always 
obtained from direct contact between the patient and the 
physician(4-8). In this sense, some researchers(7,9-10). have been 
widely discussing the gender bias regarding the use of the 
psychotropic drug.
Recent studies discussing the use of BZD by women 
have been performed in countries such as France(5), 
Norway(9), USA(6,11), Canada(7,12), United Kingdom(13), 
Spain(8,14), and Brazil(1,10,15). Such studies were conducted 
considering different health services, but few were focused 
on primary care(6,14,15).
It is worth noting that, although one of the main char-
acteristics of primary care is the work focused on preven-
tion and health promotion, medicalization has been the 
primary resource employed in mental health care by this 
department’s teams, mainly due to the scarcity of avail-
able specialized support(16). From this problem arises the 
importance of studies about the use of BZD by women in 
this setting, with emphasis to possible differences between 
Primary Health Units (PHU) and Family Health Units 
(FHU). It is our understanding that such studies can 
support discussions and contribute to a more effective 
approach of the phenomenon in the work processes of 
the teams.
We based this study on the following research questions: 
Is the prevalence of BZD use by women of a given FHU 
lower than that identified in previous studies carried out 
in other health services? Are social vulnerability situations 
such as low income or education levels and having chronic 
illnesses risk factors for the use of BZD among women cared 
for at the FHU?
Hence, the objective of this study was to estimate the 
prevalence of BZD use among adult women of an FHU in 
the state of São Paulo, Brazil, and identify the risk factors 
associated with this use, considering as parameter for com-
parison non-user women from the same unit.
METHOD
Study type
This is a quantitative cross-sectional study specifically 
developed at an FHU of a neighborhood located in between 
the periphery and the central and wealthier areas of a munic-
ipality in the state of São Paulo, Brazil.
population
The unit has a family health team and cares for 3,048 
people (931 families), of which 1,092 were women over 18 
years old.
Selection criteria
We developed this study in two phases: the first consisted 
of the identification of the number of BZD users at the unit. 
To do so, we consulted all the medical charts of women over 
18 years old (n = 1,092), as well as all the medicine dispensing 
records of the reference pharmacy corresponding to the period 
from August 2014 to August 2015 (n = 176). The consultation 
of the records aimed at obtaining a quality parameter, given 
the possible biases of the medical chart records.
The second phase of the study consisted of collecting 
information related to the social and clinical conditions of 
the BZD users (group 1) and non-users (group 2).
Sample definition
In group 1, we included information on all the BZD 
users identified in the first phase of the study (n = 81).
For group 2, we used a sample calculated from the for-
mula proposed by Luiz and Magnanini(17), considering the 
prevalences described in a previous study carried out with 
women in primary care (25.8% of the women were users of 
psychotropic drugs, and 74.2% were not)(18).
We adopted the 95% confidence level and a tolerable 
sampling error of 10%. The sample size obtained in the cal-
culation was of 70 women, whose medical charts were drawn 
from a list provided by the unit.
data collection
The data collection period was from July 2015 to March 
2016, and the sources of the clinical and sociodemographic 
data were the charts, respective registration forms, and 
the prescription records of the pharmacy of the referred 
health unit.
The data collected from the charts were the birth dates, 
the BZD prescribed, the dosage of the latest prescription, 
and whether or not there was a concomitant use of other 
psychotropics. Regarding the registration forms, we col-
lected the following data: age, education level, occupation, 
number of family members, income, whether or not the 
family received some government aid other than pension or 
retirement, and the existence of some chronic illness.
data analySiS and treatment
We inserted the data into a database created in the soft-
ware Statistical Package for the Social Sciences (IBM SPSS 
Statistics 20). We performed descriptive analyses, association 
tests (Pearson’s chi-squared or Fisher’s exact), test of differ-
ence of means or medians (Student’s t or Mann-Whitney), 
and logistic regression analysis.
We accepted the hypothesis of association or difference 
when the p-value was lower than 0.05. In the comparative 
analyses between groups, we excluded women whose missing 
data corresponded to over 30% of all collected data. Thus, 
we excluded from the data analysis 17 women who were 
BZD users. Into the logistic regression model, we inserted 
only variables that presented significance in the association 
test. We verified the model’s adequacy using the Hosmer-
Lemeshow goodness of fit test.
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RESULTS
We identified 81 BZD users among the 1,094 adult women 
cared for at the FHU, which corresponds to a 7.4% prevalence of 
BZD usage. Table 1 shows a comparative chart of the profile of 
BZD user and non-user women regarding the variables studied.
The age range of most BZD users was of 56 to 74 years 
(48.4%), while the non-users (45.7%) were in the 37 to 
55-year range. Thus, one may surmise that the mean age of 
women who used BZD was significantly higher than that 
of the non-users (p = 0.005) (Table 1).
The BZD users were also less alphabetized: 65.6% 
had at most an elementary education level, while in the 
other group 58.6% had education levels higher than the 
elementary (p = 0.005). Furthermore, 78.1% of the users 
reported having some chronic illness, and there was a dif-
ference between the two groups in this regard (p < 0.001) 
(Table 1).
Almost half of the BZD users consumed at least one 
other psychotropic drug (48.4%), presenting a significant 
difference compared to the non-users of BZD (17.1% and 
p < 0.001) (Table 1).
The BZD users also consumed a higher number of 
other psychotropic drugs (the position average of users 
was of 78.18, compared to 57.74 of non-users; p < 0.001). 
The most used psychotropics besides the BZD were 
the antidepressants.
Given that we identified the consumption of psychotro-
pics in both groups (n = 43), we verified that the majority (n 
= 35) used only one psychotropic other than BZD. Among 
the BZD users, the most consumed psychotropics other 
than BZD and antidepressants were antipsychotics (9.5%). 
For the non-users of BZD, other than antidepressants, anti-
convulsants were the most used (10%). Only BZD users 
consumed humor stabilizers (4.8%).
Regarding the self-reported illnesses, 60.4% of all par-
ticipants mentioned having some chronic disease (Figure 1), 
and the most reported illnesses in both groups were hyper-
tension and diabetes.
Table 1 – Comparison of the sociodemographic characteristics between users and non-users of benzodiazepines – São Carlos, SP, 
Brazil, 2015-2016.
Sociodemographic characteristics
Benzodiazepine User
p valueNo (n = 70) Yes (n = 64)
n % n %
Age From 18 to 36 Years 19 27.1 7 10.9
From 37 to 55 years 32 45.7 23 35.9
From 56 to 74 years 15 21.4 31 48.4
From 74 to 92 years 4 5.7 3 5.7
Mean (standard deviation) 0.005†
Non-users 48.1 (16.4)
Users 55.3 (12.9)
Education level Up to complete elementary level 29 41.4 42 65.6
0.005‡Over the complete elementary 
level 41 58.6 22 34.4
Occupation Does not work outside the home 33 47.1 34 53.1
0.489‡
Works outside the home 37 52.9 30 46.9
Number of Family members Up the three people 33 47.1 36 56.3
0.292‡
Over three people 37 52.9 28 43.8
Income† Up to two minimum wages* 20 28.6 19 29.7
0.629‡
Over two minimum wages* 26 37.1 20 31.3
Home owner§ Yes 58 82.9 55 85.9
0.118‡
No 9 12.9 3 4.7
Reports some chronic disease Yes 28 40.0 53 82.8
< 0.001‡
No 42 60.0 11 17.2
Uses another psychotropic drug Yes 12 17.1 31 48.4
< 0.001‡
No 58 82.9 33 51.6
Bolsa família|| Yes 3 4.3 3 4.7
0.852‡
No 48 68.6 41 64.1
*Monthly minimum wage at the time of data collection: R$ 880.00; †Student’s t-test; ‡Chi-squared or Fisher’s exact test; †49 participants did not 
report their income; §9 participants did not report if they were homeowners; ||39 participants did not report whether or not they were Bolsa Familia 
(Brazilian social welfare program) recipients. Note: (n = 134).
4 www.ee.usp.br/reeusp
The use of benzodiazepines by women cared for at a Family Health Unit
Rev Esc Enferm USP · 2019;53:e03419
Among the BZD users, we observed that 46.9% (n = 30) 
were hypertensive and 17.2% (n = 11) were diabetic, whereas 
in the non-user group, 22.9% (n = 16) were hypertensive 
and 10% (n = 7) were diabetic. The difference between the 
number of women that reported having hypertension in both 
groups was significant (p = 0.003).
Hypertension
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Figure 1 – Frequency of women who reported having 
some chronic illness among the users and non-users of 
benzodiazepines – São Carlos, SP, Brazil, 2015-2016.
Note: (n=134).
Regarding the number of reported illnesses, the women 
who were BZD users presented more diseases than the non-
users (position averages: 82.1 and 54.2, respectively; p < 0.001).
We used the variables representing the use of other psy-
chotropics, education level, age, and self-reported illnesses, 
whose association tests presented significant results in the 
comparison between the two groups, to create an explicative 
model about the factors associated with BZD usage. Table 
2 presents the model that best explained this use.
Consuming another psychotropic drug and having self-
reported illnesses constituted risk factors for BZD usage in 
the sample studied. The women who used other psychotro-
pics presented 5.17 times more chances of using BZD than 
those who did not, whereas women who reported having 
some chronic illness were 4.8 times more likely to use BZD 
than those who did not.
Table 2 – Factors associated with the use of benzodiazepines 
according to the final logistic regression model – São Carlos, SP, 
Brazil, 2015-2016.
Factors p value Odds ratio 
Confidence interval (95%)
Lower limit Upper limit
Use of other psychotropic 0.000 5.176 2.134 12.553
Reported illnesses 0.001 4.797 1.832 12.563
Education Level 0.180 1.828 0.757 4.415
Age 0.837 0.997 0.965 1.029
Note: (n = 134).
DISCUSSION
Regarding the age mean of the BZD users identified in 
this study (55 years), a previous research effort(6) presented 
the same mean. In another study(5), the authors reported 
an average of 57 years and stated that the proportion of 
female users increased with age, thus corroborating this 
study’s findings.
However, the prescription of such medicines for older 
patients is seen as inadequate by some authors because they 
increase the risk of falling and, consequently, of fractures, 
especially the BZDs with long half-lives. It is recommended 
that, when the use of such drugs is indispensable, low dosages 
should be prescribed and short half-life BZDs, because this 
population presents physiological modifications that inter-
fere with the metabolization of the medicines, making them 
more vulnerable to drug interactions and adverse reactions(19).
The positive correlation between advanced age and BZD 
usage is well described in the literature, so much so that 
several authors dedicate their studies exclusively to this 
population. Since aging may often be accompanied by the 
emergence of sleep disorders, anxiety, depression, and neu-
rodegenerative illnesses, it is considered that such conditions 
may contribute to the increase in psychotropic consumption 
in this phase of life(7)
The women in both groups of this study’s sample had 
low education levels, but this index was higher among the 
BZD users. The education level has been described as an 
important factor related to the onset of health problems 
both for the women themselves as for the children under 
their care. Besides, in a previous study carried out in primary 
care, it was observed that people with low education levels 
are 1.7 times more likely to use psychotropics(18).
There was a significant difference between BZD users 
and non-users regarding the education level. Women who 
used BZD were those who least studied (65.6%). However, 
this risk factor did not show to be significant in the final 
regression model. It is our understanding that such a condi-
tion may reduce access to information about the damages 
related to chronic BZD usage.
Furthermore, a low education level is directly linked to 
the higher difficulty of having good professional and social-
ascension chances, “possibly contributing to a worse qual-
ity of life, odds of developing Common Mental Disorders 
and, consequently, an increase in the probability of using 
psychotropics”(18).
Regarding the profile of the families to which the 
women in the study belonged, we identified they were, in 
general, constituted by three to four people, with own hous-
ing and non-beneficiaries of governmental social programs. 
Concerning family income, we observed a predominance 
of women who reported earning over two minimum wages 
in both groups, but the interpretation of this result is lim-
ited due to the large percentage of missing data regarding 
this variable.
Nevertheless, considering the characteristics of the ter-
ritory in which the FHU is located, it is suggested that this 
study’s population was composed of women who did not 
appear to present significant social vulnerabilities despite 
the low education levels and the non-exercise of paid work 
by most of them.
We identified that 7.4% of the adult women registered 
in the referred health unit were BZD users. Prevalence is a 
data difficult to analyze, seeing that among the studies there 
are population peculiarities as well as differences regarding 
the location studied, sampling strategies, and data sources 
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employed – factors that may determine the prevalence 
variations. Furthermore, we understand that the sociode-
mographic characteristics specific to each study’s population 
may also contribute to the variability.
Thus, the prevalence described in previous stud-
ies(5,6,16,18-20) varies between 2.5% and 16.8%. Among the 
studies carried out in primary care, one of them(19) reports 
the prevalence of 2.5% of women who were BZD users; 
however, for data collection, the authors used only people 
who were BZD users in the previous six months from data 
obtained by the city’s information system.
Another study(18) performed at a PHU presented, from 
primary data, a prevalence of 13%. Hence, the prevalence 
found in this study (7.4%) was below that described in previ-
ous research. This result answers one of this study’s questions, 
suggesting that the FHUs have a more preventive focus and 
that the actions of their teams stem from a broader health 
perspective. We believe such characteristics may have con-
tributed to this finding.
An additional relevant result of this study was the iden-
tification that women with self-reported illnesses were 4.8 
times more likely to use BZD than those who did not report 
diseases. A recent research effort pointed out that patients 
who are BZD users present higher medical comorbidity lev-
els. This finding was verified from the identification that an 
increase in the frequency of medical diagnostics and higher 
rates of use of health services associated with the prescrip-
tion of this type of medicine exist(6).
The authors of the cited study proposed two explanations 
for their results: patients with a more significant number of 
clinical comorbidities are more likely to be prescribed BZD; 
and/or that the BZDs may increase the risk of adverse results 
for the health of users. Another finding of this same study is 
related to the excessive number of medical BZD prescrip-
tions to patients who presented factors that contraindicated 
their consumption such as advanced age, pulmonary diseases, 
osteoporosis, and disorders related to substance use. This 
would reflect in the worsening of the quality of life presented 
by such patients(6).
As described in Table 1, BZD users reported signifi-
cantly more chronic illnesses than non-users (p < 0.001). 
The regression model built points out that the women who 
reported some disease were almost five times more likely to 
use some type of BZD.
The two illnesses which stood out in this study in both 
groups were the chronic diseases more commonly observed 
in the general population: arterial hypertension and diabetes. 
What was notable, however, was the observation that in the 
group of BZD users, the percentage of women who reported 
arterial hypertension was more than the double. 
“The prevalence of self-reported systemic arterial hyper-
tension in Brazil is of 20.9%”(21) . In this study, 22.9% of the 
non-users of BZD were hypertensive and, among the BZD 
users, 46.9% – over the double of the general population, yet 
close to the prevalence found by a study carried out specifi-
cally with hypertensive BZD users(22).
The relationship between anxiety and arterial hyper-
tension is an old theme in the academic environment; 
nevertheless, it is not as clear as it may seem. A literature 
review(23) pointed out that many non-elucidated questions 
remain and that one illness in fact influences the other. Still, 
it described that such influence might be in varied forms 
depending, inclusively, on the individual’s type of psycho-
logical answer.
For example, the use of defense mechanisms such as 
affective dullness in the face of anxiogenic situations or 
in anxious patients may cause a drop in arterial pressure. 
Another relevant data is that the diagnosis of hypertension 
itself may cause anxiety. However, some authors state that 
prescribing anxiolytics to all hypertensive patients is not a 
good therapeutic path because hypertension is not always 
caused by anxiety or will, necessarily, generate pathological 
anxiety in patients(6,23).
The sample studied presented a higher percentage of 
diabetics (10% among non-users and 17.2% among users of 
BZD) when compared with a recent study, which indicated 
a prevalence of 6.2% of people who reported being diabetics 
in Brazil(24).
Regarding the association between having diabetes and 
using BZD, despite the percentage of women with diabetes 
being higher among the users, the association test did not 
demonstrate being a significant result (p = 0.223). Another 
Brazilian study also performed in primary care presented 
higher results(25).
Researchers from Taiwan described a higher prevalence 
of diabetes in patients with anxiety disorders (11.89%) when 
compared to the general population (5.92%)(26). The authors 
suggest two explanations for this finding: the first would 
be that physiological modifications caused by anxiety may 
generate an unbalance in the regulation of the hypothala-
mus-pituitary-adrenal pathway, resulting in high cortisol 
levels which may inhibit the function of insulin in several 
ways. The other explanation would be that the patients 
with anxiety disorders generally use psychotropic drugs 
such as antipsychotics, antidepressants, humor stabilizers, 
and benzodiazepines, which would contribute to weight 
gain and the development of hyperglycemia, hypertension, 
and hyperlipidemia(26).
An Australian longitudinal study about anxiety and 
diabetes observed that the probability of developing dia-
betes was higher among women who had persistent symp-
toms of anxiety. The two physiological explanations of the 
authors cited before were also described by the Australian 
researchers(27). Even so, due to the many confounding vari-
ables that could not be controlled, the results were not 
conclusive to the point of stating that anxiety leads to 
the development of diabetes. However, what may be con-
cluded is that only persistent symptoms of anxiety can be 
associated with a modest increase in the risk of develop-
ing diabetes(27).
Nearly half the women in this study (48.4%) reported 
using BZD concomitantly with other psychotropic medi-
cines. We also identified that using other psychotropics was 
a risk factor, that is, women who consumed other psycho-
tropics were 5.17 times more likely to use BZD than those 
who did not. The most present combination was that of 
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antidepressants and BZD, which is in agreement with pre-
vious studies(10).
The fact that nearly half the BZD users also consumed 
other psychotropic drugs may raise two suspicions, namely: 
given that diagnostics of mental disorders are generally nei-
ther unique nor static, a condition of anxiety, for example, 
may evolve to depression and vice-versa, so the association 
of psychotropics is a common practice in psychiatry and the 
BZD users probably already consumed other psychotropics 
or started using them simultaneously; the other possibility 
is that the continuous use of BZD itself, often prescribed for 
problems such as insomnia, may generate a depressive condi-
tion or another psychic problem due to the neurochemical 
transformations that the substance may cause.
There is also the potential risk of combining drugs 
that directly act on the Central Nervous System (CNS). 
Although combinations are often used for treating men-
tal illnesses, drug interactions with mild to severe effects 
may occur.
Another relevant issue is to understand that people in 
emotional suffering often somatize, making a problem of 
psychic origin physical, which leads to the consumption of 
more medicines. In this sense, in addition to this combina-
tion, some authors emphasize that individuals with common 
mental disorders are more susceptible to the prescription of 
a larger number of psychotropics and other drugs, leading 
to even more significant risks(16,18)..
Therefore, the awareness about the risks (both by users 
and by physicians and other members of the health team) 
and the materialization of the institutional support by the 
mental health specialists are essential so that the prescrip-
tion of BZD and other psychotropic drugs does not con-
stitute as a first or only therapeutic alternative for anxiety 
disorders and other mental sufferings, especially by primary 
care physicians.
This data gives rise to a critical reflection that may be 
expanded under two viewpoints. Firstly, it is questionable 
whether such prescriptions correspond to the current clinical 
condition of the users, i.e., if the diagnosis and therapeutics 
are appropriate. If the answer to this question is affirmative, 
we surmise, secondly, that the teams working in the referred 
FHU are being somewhat contingent with the mental health 
demands of the community, since, formerly, such women 
would be hospitalized or accompanied merely by the spe-
cialized services.
From these questionings, we recommend that the teams 
also pay attention to the psychosocial needs of people with 
mental disorders, discussing and undertaking efforts to 
implement social insertion and reinsertion actions as well as 
the broadening of the support networks that may be strategic 
to aiding the contention of the symptoms and the improve-
ment of the quality of life of these people, thus avoiding 
the need for using more psychotropics and/or services of 
higher complexity.
The principal limitations of this study were the use of 
secondary data, mainly due to the lack of some informa-
tion and the precariousness of the organization of the unit’s 
records, as well as the collection of data in only one health 
unit. It is our understanding that widening the sample by 
including more health services could generate even more 
significant results. For future research, we suggest the devel-
opment of a study with primary data and also using qualita-
tive techniques so to deepen the analysis of the phenomenon 
considering the perception of the users themselves.
CONCLUSION
The prevalence of BZD use among the women studied 
was smaller than the identified in previous studies in PHUs. 
Regarding the risk factors, having a chronic illness and using 
another psychotropic drug were significantly associated with 
the use of BZD, a result stemming both from the bivariate 
analyses and from logistic regression. There was a significant 
association of the education level with BZD use only in the 
bivariate analyses. Income did not constitute as an associated 
factor in any of the tests performed.
This study presents significant contributions to the 
health area. Firstly, one must observe the issues related to the 
identification of risk factors because, in the current context 
marked by strong gender discrimination, being a woman 
by itself characterizes a vulnerability situation. Hence, the 
characteristics we identified in this sample such as low 
education level, high average age, and having a chronic ill-
ness emphasize a set of risk factors to which women are 
exposed. We also highlight that, as shown in the results, 
many women probably have the diagnostic of some mental 
disorder, given the use of several psychotropic drugs, includ-
ing antipsychotics.
Secondly, it is worth stressing the issues related to 
the conscious prescription of BZD, because an aspect 
that deserves emphasis refers to the risks of drug asso-
ciation in using substances that directly act on the CNS. 
As pointed out in this study, such an association may be 
even more aggravated in this population due to the high 
rate of self-referred chronic illnesses, especially diabetes 
and hypertension, seeing that, besides the psychotropics, 
there is also the consumption of medicines to control 
such diseases.
It is also necessary to underscore the identification of 
more vulnerable groups regarding BZD use, i.e., when also 
considering the potential health risks that the chronic use of 
BZD might cause, we conclude that the group that should 
receive more attention regarding the consumption of this 
substance is that of middle-aged women or older, with low 
education levels, and chronic illnesses.
In short, it is our understanding that the FHU teams 
need the support of mental health teams to widen their offer 
of community interventions and mental health promotion 
actions of psychosocial nature which are alternative and/or 
complementary to the purely medical treatment.
In view of this set of considerations, it is worth high-
lighting that nurses have a crucial role in the work pro-
cess of family health teams, and their diversified range of 
knowledge and functions is of utmost importance so that 
the recommendations proposed in this study are consid-
ered when planning the users’ care, especially in the area 
of primary care.
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RESUMO
Objetivo: Estimar a prevalência do uso de benzodiazepínicos por mulheres adultas em uma Unidade de Saúde da Família e identificar 
os fatores de risco associados a esse uso. Método: Estudo quantitativo de corte transversal, que se utilizou de dados secundários, 
desenvolvidos em uma Unidade de Saúde da Família do interior de São Paulo. Os dados foram coletados entre a partir das seguintes fontes: 
prontuários, fichas cadastrais e arquivo de receitas da farmácia da referida unidade de saúde. Foram utilizados os testes qui-quadrado, 
t de Student, Mann-Whitney e análise de regressão logística. Resultados: Foram identificadas 81 usuárias de benzodiazepínicos entre 
1.094 mulheres adultas (7,4%). Em relação aos fatores de risco, a comparação dos grupos de usuárias (n  =  64) e não usuárias de 
benzodiazepínicos (n = 70) apontou que ter doença crônica e usar outro psicotrópico foram significativamente associados ao uso de 
benzodiazepínicos. Conclusão: A prevalência encontrada foi menor do que a descrita em estudos prévios realizados em Unidades 
Básicas de Saúde. O grupo que deve receber maior atenção em relação ao consumo de benzodiazepínicos é o de mulheres de meia-idade 
ou mais, com pouca escolaridade e doença crônica.
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RESUMEN
Objetivo: Estimar la prevalencia del empleo de benzodiazepinas por mujeres adultas en una Unidad de Salud de la Familia e identificar 
los factores de riesgo asociados con dicho uso. Método: Estudio cuantitativo de cohorte transversal, que se utilizó de datos secundarios, 
desarrollados en una Unidad de Salud de la Familia del interior de São Paulo. Los datos fueron recogidos de las siguientes fuentes: 
fichas médicas, fichas de registro y archivo de recetas de la farmacia de la mencionada unidad de salud. Fueron utilizadas las pruebas 
de Chi cuadrado, t de Student, Mann-Whitney y análisis de regresión logística. Resultados: Fueron identificadas 81 usuarias de 
benzodiazepinas entre 1.094 mujeres adultas (7,4%). Con respecto a los factores de riesgo, la comparación de los grupos de usuarias (n = 
64) y no usuarias de benzodiazepinas (n = 70) señaló que tener enfermedad crónica y usar otro psicótropo estuvieron significativamente 
asociados con el uso de benzodiazepinas. Conclusión: La prevalencia encontrada fue menor que la descrita en estudios previos realizados 
en Unidades Básicas de Salud. El grupo que debe recibir mayor atención con relación al consumo de benzodiazepinas es el de mujeres 
de mediana edad o más, con poca escolaridad y enfermedad crónica.
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